431
Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Condition(s):Multiple Myeloma in RelapseLast Updated:March 1, 2023Active, not recruiting
Stage III Multiple Myeloma: 436 Clinical Trials, Page 44 of 44
Hide Studies Not Open or Pending
432
Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma
Condition(s):Breast Cancer; Kidney Cancer; Lymphoma; Melanoma; Multiple Myeloma; Sarcoma; Unspecified Adult Solid Tumor, Protocol SpecificLast Updated:October 14, 2015Completed
433
Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy
Condition(s):Multiple MyelomaLast Updated:November 25, 2013Completed
434
The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma – Myeloma XII (ACCoRd)
Condition(s):Multiple MyelomaLast Updated:June 19, 2018Recruiting
435
IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:February 5, 2009Completed
436
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Condition(s):Previously Untreated Symptomatic Multiple MyelomaLast Updated:April 27, 2023Active, not recruiting